Trastuzumab deruxtecan in patients with central nervous system involvement from HER2-positive breast cancer: The DEBBRAH trial.

José Manuel Pérez-García,Marta Vaz Batista,Patricia Cortez,Manuel Ruiz-Borrego,Juan Miguel Cejalvo,Juan de la Haba-Rodriguez,Laia Garrigós,Fabricio Racca,Sonia Servitja,Salvador Blanch,María Gion,Monica Nave,María Fernández-Abad,Alejandro Martinez-Bueno,Antonio Llombart-Cussac,Miguel Sampayo-Cordero,Andrea Malfettone,Javier Cortés,Sofía Braga

Neuro-oncology（2023）

引用 83|浏览29

暂无评分

摘要

T-DXd showed intracranial activity with manageable toxicity and maintained the quality of life in pretreated HER2-positive ABC patients with stable, untreated, or progressing BMs. Further studies are needed to validate these results in larger cohorts.

查看译文

关键词

HER2-positive,T-DXd,advanced breast cancer,brain metastases,trastuzumab deruxtecan

AI 理解论文

溯源树

样例

生成溯源树，研究论文发展脉络

Chat Paper

正在生成论文摘要